Rituximab can treat membranous nephropathy and the effect is usually more significant with fewer side effects, but it should be used under doctor’s supervision according to the condition. Membranous nephropathy is mostly caused by anti-PLA2R antibody binding to the receptor on the glomerulus, leading to glomerular immune reaction, causing glomerular injury, glomerular filtration dysfunction, and massive proteinuria. Rituximab is a kind of immunosuppressant, which can specifically bind to the antibody of B cells, reduce the content of antibody in membranous nephropathy, reduce the formation of immune complexes in the glomerulus, and reduce glomerular injury, thus reducing proteinuria and stabilizing renal function. At present, rituximab as a biological agent has been used in the treatment of many kidney diseases, which can not only reduce the recurrence rate of proteinuria, but also reduce the application of hormones. It is recommended that patients with membranous nephropathy seek timely medical treatment, active treatment under the guidance of a physician, drugs need to be used as prescribed by the doctor, do not self-medication.